短程大分割质子束放疗联合18F-DOPA PET与增强MRI靶向治疗新诊断胶质母细胞瘤65岁及以上患者:单臂2期试验
这项单臂2期试验纳入39例接受治疗的65岁及以上新诊断胶质母细胞瘤患者,采用18F-DOPA PET和增强MRI定义靶区的大分割质子束放疗联合替莫唑胺。12个月总生存率为56%(95%CI 39-72),中位总生存13.1个月(95%CI 11.1-19.1),3级治疗相关不良事件为中枢神经系统坏死4例(10%)和血小板减少1例(3%)。
要点
- 39例可评估患者12个月总生存率为56%(95%CI 39-72),中位总生存13.1个月(95%CI 11.1-19.1)。
- 3级基线校正治疗相关不良事件为CNS坏死4例(10%)和血小板减少1例(3%),无4级事件或死亡。
- 作者认为该方案较历史对照总生存改善且不良事件谱有前景,已启动2期研究(NCT05781321)对比标准治疗。
核心结论
- 作者观察到采用18F-DOPA PET引导的大分割质子束放疗联合替莫唑胺较历史对照总生存改善,且不良事件谱有前景。
- 这些发现促使启动一项2期研究(NCT05781321),在任意年龄新诊断胶质母细胞瘤成人中比较该方案与标准治疗。
研究设计与样本
- 单臂2期试验,纳入两个Mayo Clinic院区(美国亚利桑那州凤凰城和明尼苏达州罗切斯特)65岁及以上、ECOG体能状态评分0-2、新诊断WHO 4级恶性胶质母细胞瘤患者。
- 放疗靶区由18F-DOPA PET和MRI对比增强区域定义。
- 患者接受剂量递增大分割质子束放疗(35-40 Gy等效剂量,分5次或10次)联合口服同步替莫唑胺(75 mg/m2每日,5次方案为第1-7天,10次方案为第1-14天),放疗完成后1个月给予辅助替莫唑胺(150-200 mg/m2,第1-5天,共6个28天周期)。
- 主要终点为入组后12个月总生存;主要终点和安全性在意向治疗人群(定义为所有开始放疗的合格患者)中评估。
- 2019年5月22日至2021年5月25日共入组43例,其中4例未接受治疗(进展2例、死亡1例、保险拒付1例),39例接受治疗(中位年龄70.2岁[IQR 67.4-74.3];女性11例[28%],男性28例[72%];白人37例[95%],黑人或非裔美国人1例[3%],1例选择不披露种族)。
主要发现
- 截至数据截止日(2024年1月30日),中位随访25.4个月(IQR 22.1-29.7)。
- 39例患者中22例(56%[95%CI 39-72])在12个月时存活。
- 中位总生存为13.1个月(95%CI 11.1-19.1)。
- 3级基线校正治疗相关不良事件为CNS坏死4例(10%)和血小板减少1例(3%)。
- 未发生基线校正治疗相关4级不良事件或死亡。
临床怎么用
- 作者认为该方案较历史对照总生存改善且不良事件谱有前景,并已据此启动2期研究(NCT05781321)比较该方案与标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6-9 months. 3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy. With improved targeting and the dosimetric advantages of proton beam therapy, we aimed to test whether hypofractionated proton beam therapy could improve survival and QOL in older patients with glioblastoma. METHODS: In this single-arm phase 2 trial, we enrolled patients aged 65 years and older with an Eastern Cooperative Oncology Group performance status score of 0-2 and newly diagnosed WHO grade 4, malignant glioblastoma from two Mayo Clinic campuses (Phoenix, AZ, and Rochester, MN, USA). Radiotherapy target volumes were defined by 18F-DOPA PET and MRI regions of contrast enhancement. Patients were given dose-escalated hypofractionated proton beam therapy (35-40 Gy equivalents in five or ten treatments) plus oral concurrent temozolomide (75 mg/m2 daily on days 1-7 for the five-treatment regimen or on days 1-14 for the ten-treatment regimen), and 1 month after completing radiotherapy patients were given adjuvant temozolomide (150-200 mg/m2 on days 1-5 for six 28-day cycles). The primary endpoint was overall survival at 12 months after enrolment. The primary endpoint and safety were assessed in the intention-to-treat population (defined as all eligible patients who started radiotherapy). This study is registered with ClinicalTrials.gov, NCT03778294, and is now complete. FINDINGS: Between May 22, 2019, and May 25, 2021, 43 patients were enrolled, of whom four did not receive treatment because of progression (n=2), death (n=1), or insurance denial (n=1), such that 39 patients received treatment (median age 70·2 years [IQR 67·4-74·3]; 11 [28%] of 39 patients were female, 28 [72%] were male, 37 [95%] were White, one [3%] was Black or African American, and one chose not to disclose their race). As of data cutoff (Jan 30, 2024), median follow-up was 25·4 months (IQR 22·1-29·7). 22 (56% [95% CI 39-72]) of 39 patients were alive at 12 months. Median overall survival was 13·1 months (95% CI 11·1-19·1). Grade 3 baseline-adjusted, treatment-associated adverse events were CNS necrosis (four [10%] of 39) and thrombocytopenia (one [3%]). No baseline-adjusted, treatment-associated grade 4 adverse events or deaths occurred. INTERPRETATION: We observed improved overall survival compared with historical controls and a promising adverse event profile by using 18F-DOPA PET-guided, dose-escalated, hypofractionated proton beam therapy. These findings have resulted in the opening of a phase 2 study (NCT05781321) investigating this regimen versus standard-of-care treatment in adults of any age with newly diagnosed glioblastoma. FUNDING: Mayo Clinic Marley Endowment Funds and the Lawrence W and Marilyn W Matteson Fund in Cancer Research.
引用
- Vora S, Pafundi D, Voss M, et al. Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial. Lancet Oncol. 2024. PMID: 39571596. doi:10.1016/S1470-2045(24)00585-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。